High Point Clinical Trials Center, LLC (HPCTC), the largest independent clinical research site in North Carolina, reports it has partnered with ProSciento, a specialized CRO exclusively focused on metabolic diseases, to join as a NASH PASS site partner.
ProSciento has organized qualified research sites and proprietary technology to improve enrollment outcomes in NASH clinical trials. HPCTC will now use the NASHPASS protocol to identify individuals eligible for enrollment in clinical trials of therapeutic candidates to treat NAFLD (non-alcoholic fatty liver disease) and NASH (steatohepatitis).
An independent clinical research site conducting clinical research studies with a focus on Phase I/II Proof of Concept clinical pharmacology research. As a NASH PASS partner, High Point Clinical Trials Center will contribute to the expansion and enrichment of its database of prospective clinical study participants evaluated for NAFLD/NASH by utilizing a combination of transient elastography (Fibroscan), proprietary algorithms, and non-invasive biomarker testing.
HPCTC Executive Perspective
Dr. Lorraine M. Rusch, President of HPCTC noted “NAFLD/NASH represents a rapidly growing and evolving field of biopharmaceutical R&D, with a sizeable number of drug candidates advancing through the various stages of preclinical and clinical development. I am delighted that our team joins ProSciento and HPCTC have come together to lead the commercial research industry in metabolic disease patient enrichment. These much-needed efforts will spur rapid recruitment of patients into clinical trials which directly translates into novel pharmaceutical products and new methodologies for earlier treatment of this emerging metabolic epidemic.
Founded in 2009, this research site purports to be the largest independent clinical research unit in North Carolina. They conduct the full range of clinical trial phases, with special focus on Phase I/II translational medicine studies including First-in-Human, clinical Proof of Concept and the traditional IND/NDA-enabling clinical pharmacology programs for Contract Research Organization, biotechnology and pharmaceutical companies globally.
President Lorraine M. Rusch has nearly two decades of clinical development experience. HPCTC employs approximately 50 to 75 employees.
ProSciento is a leading specialty CRO focused exclusively on NASH, diabetes, obesity and related metabolic diseases. Building on 15 years of experience and more than 280 metabolic clinical projects conducted, they provide customized clinical research services for multinational, early development clinical trial programs designed to offer clients an advantage in the rapidly evolving landscape of metabolic drug and device development. Based in San Diego, CA, they employ between 125 and 150.